Financial

February 2, 2024

Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference

Learn more

Financial

January 30, 2024

Johnson & Johnson to Participate in the TD Cowen 44th Annual Health Care Conference

Learn more

Financial

January 23, 2024

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2023.

Learn more

Corporate

January 8, 2024

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson’s Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics

Learn more

Financial

January 2, 2024